Examining the Long-term Clinical Evidence of Therapies for Inflammatory Bowel Disease in Bio-naïve Patients : Episode 15

Video

July 19, 2023

Utilizing JAK Inhibitors in Patients With UC

Author(s):

David P. Hudesman, MD,Maia Kayal, MD

Experts discuss how they utilize Janus kinase (JAK) inhibitors for patients with ulcerative colitis (UC).

EP: 1.Overview of IBD

EP: 2.Treatment Factors of IBD

EP: 3.Managing Care for IBD Patients Not Responding to Treatment

EP: 4.Selecting First-Line Treatments for CD

EP: 5.The Role of Vedolizumab and Risankizumab in CD

EP: 6.Efficacy and Safety of Ustekinumab for CD

EP: 7.Selecting Therapies for CD in Pregnancy

EP: 8.Selecting Treatments in Patients With EIM

EP: 9.Second-Line Therapies for CD

EP: 10.Optimizing Therapies for CD

EP: 11.Major Takeaways for Treating CD

EP: 12.Treatment Approaches for Patients With UC

EP: 13.The Role of Ozanimod in UC

EP: 14.The Role of Ustekinumab in UC

EP: 15.Utilizing JAK Inhibitors in Patients With UC

EP: 16.Treatment Sequencing for UC

EP: 17.Biosimilar Treatment Options for Patients With UC

EP: 18.Key Takeaways and Prospective Treatment Advances

Related Videos

Christine Frissora, MD | Credit: Weill Cornell

Parent Stress Reduces Over Time When Weaning Child Off Tube Feeding with Hide Okuno, MS

Age, Race, Ethnicity Disparities Hinder Celiac Disease Screening, with Debra Silberg, MD, PhD

$Lauren Collen, MD: Advanced Combination Therapy May Be Effective Option for Pediatric Refractory IBD$

Related Content

Related Content

Do Not Sell My Information

Terms & Conditions

Contact Info

2 Commerce Drive
Cranbury, NJ 08512

© 2024 MJH Life Sciences

All rights reserved.